Estimated Lifetime Gained With Cancer Screening Tests: A Meta-Analysis of Randomized Clinical Trials | Cancer Screening, Prevention, Control | JAMA Internal Medicine | JAMA Network https://t.co/UaJKuCDqNp
New fun paper with @CatarinaBarata5@NoelCodella@HaraldKittler and others about improving model performance *in the ways we as clinicians care about* by incorporating human preferences! https://t.co/7dHbRTCYEq
Atopic dermatitis presents differently across the lifespan. This manuscript reviewed the presentation of eczema across age groups. https://t.co/CmNC2XWPmZ
Advice for JAAD reviewers ➡️ Readers value concise, well-written manuscripts. We depend on our reviewers to ensure the quality and readability of each manuscript. A good reviewer knows the basics, whereas a great reviewer continually hones those skills. https://t.co/ZVQ3OG9h6w
The @US_FDA granted accelerated approval to retifanlimab-dlwr (Zynyz) for adult patients with metastatic or recurrent locally advanced Merkel cell carcinoma. Learn more in #DermWorldWeekly. https://t.co/WDzPYWOeW8
In questi tempi difficili che stiamo attraversando, rispondiamo nella fede agli appelli che lo Spirito Santo ci rivolge, affinché diamo prova di #solidarietà verso le persone che incontriamo e che contano sul nostro sostegno fraterno.
Brain and spine imaging for children with congenital melanocytic nevi is controversial. This study suggests that imaging may not be needed for children with a few small CMNs and no medium or giant CMNs or 1 CMN of any size may not require imaging. https://t.co/632IAQ51U9
Renew your membership, or become a new member of the #IDS if you haven’t yet done so here: https://t.co/5RaTj17pdU
Get 20% off these valuable resources on #dermatoscopy by using code IDS22. Place an order visit: https://t.co/Fd6uSkPhMn and enter the code at checkout.
the past and future of skin cancer prevention between 2000 and 2020... from secondary (early diagnosis) to tertiary (effective treatment of even advanced cancers) prevention. In 20 years I experienced two revolutions - dermoscopy and oncologic treatment -…https://t.co/hNwKCzYniH
We are pleased to announce that JAAD has achieved a 2021 Impact Factor of 15.487, making it the #1 journal in dermatology for three years in a row. Thank you to all journal contributors for helping dermatologists improve patient outcomes.